Which diabetes drug wins for heart failure? massive study seeks answers
NCT ID NCT06980623
First seen Dec 16, 2025 · Last updated May 25, 2026 · Updated 23 times
Summary
This study looks at two diabetes medications, tirzepatide and semaglutide, in 26,000 adults with type 2 diabetes and a type of heart failure called HFpEF. The goal is to see which drug better prevents hospitalizations for heart failure and death. Participants are already taking one of the drugs as part of their routine care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States
Conditions
Explore the condition pages connected to this study.